Options activity is heating up across several names this week. Earnings catalysts and sharp price moves are drawing traders in.
The Trade Desk heads into its Q1 print with options expiries stacked through July. The stock is down 37% year-to-date. Its short score sits at 56. Bears are on the defensive, per ORTEX data, making the setup asymmetric into results.
Apellis Pharmaceuticals tells a different story. The biotech is up 64% YTD and carries an RSI of 87. A Biogen takeover narrative is reshaping sentiment. Options open interest is concentrated in May and June expiries — near-term bets dominate.
XPeng stands out among the highest-scoring options names this week. Its ORTEX options score leads mid-cap stocks. Short interest is heavy at 8.1 days to cover. Analysts see 55% upside. That combination draws both directional bets and hedges.
Cytokinetics also ranks high on options momentum. The biotech carries a short score of 62. A clinical catalyst is looming. Options chains run only through July — a tight window for a binary event.
MaxLinear is the most dramatic story in the group. The semiconductor stock is up 366% year-to-date. RSI sits at 88. Options activity is skewed bullish. Only two expiry dates exist — May 15 and June 18 — signalling concentrated near-term positioning. The June 18 expiry captures any earnings reaction.
The common theme this week: earnings-driven positioning ahead of May prints, with bulls and bears stacking chips in a narrow window.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
